1,217 research outputs found
Functionality of primary hepatic non-parenchymal cells in a 3D spheroid model and contribution to acetaminophen hepatotoxicity.
In addition to hepatocytes, the liver comprises a host of specialised non-parenchymal cells which are important to consider in the development of in vitro models which are both physiologically and toxicologically relevant. We have characterized a 3D co-culture system comprising primary human hepatocytes (PHH) and non-parenchymal cells (NPC) and applied it to the investigation of acetaminophen-induced toxicity. Firstly, we titrated ratios of PHH:NPC and confirmed the presence of functional NPCs via both immunohistochemistry and activation with both LPS and TGF-β. Based on these data we selected a ratio of 2:1 PHH:NPC for further studies. We observed that spheroids supplemented with NPCs were protected against acetaminophen (APAP) toxicity as determined by ATP (up to threefold difference in EC50 at day 14 compared to hepatocytes alone) and glutathione depletion, as well as miR-122 release. APAP metabolism was also altered in the presence of NPCs, with significantly lower levels of APAP-GSH detected. Expression of several CYP450 enzymes involved in the bioactivation of APAP was also lower in NPC-containing spheroids. Spheroids containing NPCs also expressed higher levels of miRNAs which have been implicated in APAP-induced hepatotoxicity, including miR-382 and miR-155 which have potential roles in liver regeneration and inflammation, respectively. These data indicate that the interaction between hepatocytes and NPCs can have significant metabolic and toxicological consequences important for the correct elucidation of hepatic safety mechanisms
Neural changes following cognitive behaviour therapy for psychosis: a longitudinal study
A growing body of evidence demonstrates that persistent positive symptoms, particularly delusions, can be improved by cognitive behaviour therapy for psychosis. Heightened perception and processing of threat are believed to constitute the genesis of delusions. The present study aimed to examine functional brain changes following cognitive behaviour therapy for psychosis. The study involved 56 outpatients with one or more persistent positive distressing symptoms of schizophrenia. Twenty-eight patients receiving cognitive behaviour therapy for psychosis for 6–8 months in addition to their usual treatment were matched with 28 patients receiving treatment as usual. Patients’ symptoms were assessed by a rater blind to treatment group, and they underwent functional magnetic resonance imaging during an affect processing task at baseline and end of treatment follow-up. The two groups were comparable at baseline in terms of clinical and demographic parameters and neural and behavioural responses to facial and control stimuli. The cognitive behaviour therapy for psychosis with treatment-as-usual group (22 subjects) showed significant clinical improvement compared with the treatment-as-usual group (16 subjects), which showed no change at follow-up. The cognitive behaviour therapy for psychosis with treatment-as-usual group, but not the treatment-as-usual group, showed decreased activation of the inferior frontal, insula, thalamus, putamen and occipital areas to fearful and angry expressions at treatment follow-up compared with baseline. Reduction of functional magnetic resonance imaging response during angry expressions correlated directly with symptom improvement. This study provides the first evidence that cognitive behaviour therapy for psychosis attenuates brain responses to threatening stimuli and suggests that cognitive behaviour therapy for psychosis may mediate symptom reduction by promoting processing of threats in a less distressing way
On the Nature of the X-ray Emission from the Ultraluminous X-ray Source, M33 X-8: New Constraints from NuSTAR and XMM-Newton
We present nearly simultaneous NuSTAR and XMM-Newton observations of the
nearby (832 kpc) ultraluminous X-ray source (ULX) M33 X-8. M33 X-8 has a 0.3-10
keV luminosity of LX ~ 1.4 x 10^39 erg/s, near the boundary of the
"ultraluminous" classification, making it an important source for understanding
the link between typical Galactic X-ray binaries and ULXs. Past studies have
shown that the 0.3-10 keV spectrum of X-8 can be characterized using an
advection-dominated accretion disk model. We find that when fitting to our
NuSTAR and XMM-Newton observations, an additional high-energy (>10 keV)
Comptonization component is required, which allows us to rule out single
advection-dominated disk and classical sub-Eddington models. With our new
constraints, we analyze XMM-Newton data taken over the last 17 years to show
that small (~30%) variations in the 0.3-10 keV flux of M33 X-8 result in
spectral changes similar to those observed for other ULXs. The two most likely
phenomenological scenarios suggested by the data are degenerate in terms of
constraining the nature of the accreting compact object (i.e., black hole
versus neutron star). We further present a search for pulsations using our
suite of data; however, no clear pulsations are detected. Future observations
designed to observe M33 X-8 at different flux levels across the full 0.3-30 keV
range would significantly improve our constraints on the nature of this
important source.Comment: Accepted for publication in ApJ (15 pages, 4 tables, 6 figures
Acute Metabolic Switch Assay Using Glucose/Galactose Medium in HepaRG Cells to Detect Mitochondrial Toxicity.
Using galactose instead of glucose in the culture medium of hepatoma cell lines, such as HepG2 cells, has been utilized for a decade to unmask the mitochondrial liability of chemical compounds. A modified glucose-galactose assay on HepG2 cells, reducing the experimental period for screening of mitochondrial toxicity to 2 to 4 hr, has been previously reported. HepaRG cells are one of the few cell lines that retain some of the important characteristics of human hepatocytes, offering advantages of working with a cell line, therefore, are considered an alternative for HepG2 cells in drug toxicity screening. A method is described here using HepaRG cells in an acute metabolic switch assay utilizing specific glucose/galactose media, a combined ATP-protein-LDH assay measuring three endpoints from one 96-well plate, and a criteria to label a compound as a mitochondrial toxin. © 2019 by John Wiley & Sons, Inc
Novel in vitro and mathematical models for the prediction of chemical toxicity
The
focus
of
much
scientific
and
medical
research
is
directed
towards
understanding
the
disease
process
and
defining
therapeutic
intervention
strategies.
Whilst
the
scientific
basis
of
drug
safety
has
received
relatively
little
attention,
despite
the
fact
that
adverse
drug
reactions
(ADRs)
are
a
major
health
concern
and
a
serious
impediment
to
development
of
new
medicines.
Toxicity
issues
account
for
~21%
drug
attrition
during
drug
development
and
safety
testing
strategies
require
considerable
animal
use.
Mechanistic
relationships
between
drug
plasma
levels
and
molecular/cellular
events
that
culminate
in
whole
organ
toxicity
underpins
development
of
novel
safety
assessment
strategies.
Current
in
vitro
test
systems
are
poorly
predictive
of
toxicity
of
chemicals
entering
the
systemic
circulation,
particularly
to
the
liver.
Such
systems
fall
short
because
of
1)
the
physiological
gap
between
cells
currently
used
&
human
hepatocytes
existing
in
their
native
state,
2)
the
lack
of
physiological
integration
with
other
cells/systems
within
organs,
required
to
amplify
the
initial
toxicological
lesion
into
overt
toxicity,
3)
the
inability
to
assess
how
low
level
cell
damage
induced
by
chemicals
may
develop
into
overt
organ
toxicity
in
a
minority
of
patients,
4)
lack
of
consideration
of
systemic
effects.
Reproduction
of
centrilobular
&
periportal
hepatocyte
phenotypes
in
in
vitro
culture
is
crucial
for
sensitive
detection
of
cellular
stress.
Hepatocyte
metabolism/phenotype
is
dependent
on
cell
position
along
the
liver
lobule,
with
corresponding
differences
in
exposure
to
substrate,
oxygen
&
hormone
gradients.
Application
of
bioartificial
liver
(BAL)
technology
can
encompass
in
vitro
predictive
toxicity
testing
with
enhanced
sensitivity
and
improved
mechanistic
understanding.
Combining
this
technology
with
mechanistic
mathematical
models
describing
intracellular
metabolism,
fluid-‐flow,
substrate,
hormone
and
nutrient
distribution
provides
the
opportunity
to
design
the
BAL
specifically
to
mimic
the
in
vivo
scenario.
Such
mathematical
models
enable
theoretical
hypothesis
testing,
will
inform
the
design
of
in
vitro
experiments,
and
will
enable
both
refinement
and
reduction
of
in
vivo
animal
trials.
In
this
way,
development
of
novel
mathematical
modelling
tools
will
help
to
focus
and
direct
in
vitro
and
in
vivo
research,
and
can
be
used
as
a
framework
for
other
areas
of
drug
safety
science
Multiscale modelling of drug transport and metabolism in liver spheroids
In early preclinical drug development, potential candidates are tested in the laboratory using isolated cells. These in vitro experiments traditionally involve cells cultured in a two-dimensional monolayer environment. However, cells cultured in three-dimensional spheroid systems have been shown to more closely resemble the functionality and morphology of cells in vivo. While the increasing usage of hepatic spheroid cultures allows for more relevant experimentation in a more realistic biological environment, the underlying physical processes of drug transport, uptake and metabolism contributing to the spatial distribution of drugs in these spheroids remain poorly understood. The development of a multiscale mathematical modelling framework describing the spatio-temporal dynamics of drugs in multicellular environments enables mechanistic insight into the behaviour of these systems. Here, our analysis of cell membrane permeation and porosity throughout the spheroid reveals the impact of these properties on drug penetration, with maximal disparity between zonal metabolism rates occurring for drugs of intermediate lipophilicity. Our research shows how mathematical models can be used to simulate the activity and transport of drugs in hepatic spheroids and in principle any organoid, with the ultimate aim of better informing experimentalists on how to regulate dosing and culture conditions to more effectively optimize drug delivery
Enhanced hepatic respiratory capacity and altered lipid metabolism support metabolic homeostasis during short-term hypoxic stress.
BACKGROUND: Tissue hypoxia is a key feature of several endemic hepatic diseases, including alcoholic and non-alcoholic fatty liver disease, and organ failure. Hypoxia imposes a severe metabolic challenge on the liver, potentially disrupting its capacity to carry out essential functions including fuel storage and the integration of lipid metabolism at the whole-body level. Mitochondrial respiratory function is understood to be critical in mediating the hepatic hypoxic response, yet the time-dependent nature of this response and the role of the respiratory chain in this remain unclear. RESULTS: Here, we report that hepatic respiratory capacity is enhanced following short-term exposure to hypoxia (2 days, 10% O2) and is associated with increased abundance of the respiratory chain supercomplex III2+IV and increased cardiolipin levels. Suppression of this enhanced respiratory capacity, achieved via mild inhibition of mitochondrial complex III, disrupted metabolic homeostasis. Hypoxic exposure for 2 days led to accumulation of plasma and hepatic long chain acyl-carnitines. This was observed alongside depletion of hepatic triacylglycerol species with total chain lengths of 39-53 carbons, containing palmitic, palmitoleic, stearic, and oleic acids, which are associated with de novo lipogenesis. The changes to hepatic respiratory capacity and lipid metabolism following 2 days hypoxic exposure were transient, becoming resolved after 14 days in line with systemic acclimation to hypoxia and elevated circulating haemoglobin concentrations. CONCLUSIONS: The liver maintains metabolic homeostasis in response to shorter term hypoxic exposure through transient enhancement of respiratory chain capacity and alterations to lipid metabolism. These findings may have implications in understanding and treating hepatic pathologies associated with hypoxia.GlaxoSmithKlin
Measurement of CD4+ and CD8+ T-Lymphocyte Cytokine Secretion and Gene Expression Changes in p-Phenylenediamine Allergic Patients and Tolerant Individuals
Factors predisposing to individual susceptibility to contact allergic dermatitis are ill defined. This study was designed to characterize the response of allergic and tolerant individuals’ T-lymphocytes after exposure to p-phenylenediamine (PPD). Peripheral blood mononuclear cells (PBMCs) from allergic patients proliferated when treated with PPD and Bandrowski's base (BB) and secreted IL-1α, -1β, -4, -5, -6, -8, -10, and -13; IFN-γ; tumor necrosis factor-α; MIP-1α/β; MCP-1 (monocyte chemotactic protein-1); and RANTES. PBMCs from tolerant individuals were stimulated to proliferate only with BB, and they secreted significantly lower levels of Th2 cytokines. Principal component analysis showed that genes are differentially expressed between the patient groups. A network-based analysis of microarray data showed upregulation of T helper type 2 (Th2) gene pathways, including IL-9, in allergic patients, but a regulatory gene profile in tolerant individuals. Real-time PCR confirmed the observed increase in Th2 cytokine gene transcription in allergic patients. Purified CD4+ and CD8+ T cells from allergic patients were stimulated to proliferate and secrete Th2 cytokines following antigen exposure. Only CD4+ T cells from tolerant individuals were stimulated by BB, and levels of Th2 cytokines were 80% lower. The nature of the antigenic determinant stimulating PBMCs and levels of Th2 cytokines, including IL-9, was confirmed in a validation cohort. These studies show increased activity of Th2 cytokines in CD4+ and CD8+ T cells from individuals with allergic contact dermatitis
- …